Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7
Original Research
![Noteworthy comment: The results of this research led to recommendations for improvement and the potential extrapolation of these best practices to other HTA organizations worldwide, along with suggestions for pan-Canadian Oncology Drug Review (pCODR’s) continued evolution in conjunction with its integration into Canadian Agency for Drugs and Technologies in Health (CADTH). It is clear that the transition of pCODR to CADTH provides an opportunity for these newly-amalgamated HTA agencies in Canada](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
20,503 | Dovepress* | 18,578+ | 2,217 | 20,795 | |
PubMed Central* | 1,925 | 601 | 2,526 | ||
Totals | 20,503 | 2,818 | 23,321 | ||
*Since 3 June 2015 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
32 | 1 | 0 | 0 | 14 | 17 |
View citations on PubMed Central and Google Scholar